The present invention relates to compounds of the general formula (I) whereinR is methyl; and R1 is 4-methyl-4-oxy-piperazin-l-yl; or R is CH2OH and R1 is4-methyl-piperazin-l-yl or is 4-methyl-4-oxy-piperazin-l-yl; and topharmaceutically acceptable acid addition salts thereof for the treatment ofNK-I receptor related diseases.